Catalyst Event
Vertex Pharmaceuticals Inc (VRTX) · Other
From Akros U.S. Tech 100 Index (AUT100)
6/1/2026, 12:00:00 AM
The U.S. FDA accepted Vertex's Biologics License Application (BLA) for povetacicept for the treatment of IgA nephropathy (IgAN) on June 1, 2026, granting it priority review. High importance is estimated due to the potential for >10% valuation impact from this major pipeline asset, with a PDUFA date of November 30, 2026, expected.
Korean Translation
미국 FDA, 2026년 6월 1일 IgA 신증(IgAN) 치료를 위한 포베타시셉트의 생물의약품 허가 신청(BLA)을 우선 심사 대상으로 접수함. 주요 신약의 우선 심사 승인에 따른 10% 이상의 기업 가치 상승이 예상되며, PDUFA 목표일은 2026년 11월 30일로 예정됨.
Related Recent Events
Lumentum Holdings Inc (LITE) · Earnings Release
Lumentum's next earnings release for Q4 2026 is scheduled for August 11, 2026; high importance as a primary volatility driver scheduled.
8/11/2026, 12:00:00 AM
Rocket Lab Corp (RKLB) · Earnings Release
Second Quarter 2026 financial results and conference call are scheduled for 2026-08-06 scheduled.
8/6/2026, 12:00:00 AM
Fortinet Inc (FTNT) · Earnings Release
Fortinet is scheduled to announce its Q2 2026 earnings results on August 5, 2026 expected. Medium importance estimated as earnings releases typically cause >5% price volatility.
8/5/2026, 12:00:00 AM
Teradyne Inc (TER) · Earnings Release
High importance is estimated as earnings reports typically drive significant volatility; Q2 2026 earnings release with revenue guidance of $1.15B-$1.25B and non-GAAP EPS of $1.86-$2.15 is scheduled.
8/4/2026, 12:00:00 AM
Axon Enterprise Inc (AXON) · Earnings Release
Market impact is estimated at Medium (>=5%) based on historical earnings volatility; Axon's Q2 2026 earnings report is scheduled.
8/3/2026, 12:00:00 AM
Amazon.com Inc (AMZN) · Earnings Release
Amazon's Q2 2026 earnings release is expected on July 30, 2026. The company guided for net sales between $194.0 billion and $199.0 billion. Low importance is assigned as the market reaction has not yet occurred expected.
7/30/2026, 12:00:00 AM